SCHEMBL8108460

SCHEMBL8108460

C[C@@H]1CN(c2ccc(Cl)c(F)c2)CCN1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2A1 Q16548 2/20 0.55
MAPT P10636 2/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
KHK P50053 2/20 0.45
HSD11B1 P28845 1/20 0.45
ADRB1 P08588 1/20 0.44
RAD51 Q06609 1/20 0.39
MMP2 P08253 1/20 0.38
ADAMTS5 Q9UNA0 1/20 0.38
CHRM2 P08172 1/20 0.38
CHRM5 P08912 1/20 0.38
CHRM1 P11229 1/20 0.38
CHRM3 P20309 1/20 0.38
SLC6A2 P23975 2/20 0.37
SLC6A4 P31645 2/20 0.37
SLC6A3 Q01959 1/20 0.37
CDK1 P06493 1/20 0.37
CDK4 P11802 1/20 0.37
CCNA2 P20248 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8108416 0.88 BCL2A1 (0.52) BCL2A1MAPTALDH1A1LMNAKHK
SCHEMBL8110875 0.86 MAPT (0.49) BCL2A1MAPTALDH1A1LMNAKHK
SCHEMBL4936462 0.86 BCL2A1 (0.66) BCL2A1MAPTALDH1A1LMNAKHK
SCHEMBL20159005 0.86 MAPT (0.49) BCL2A1MAPTALDH1A1LMNAKHK
SCHEMBL18013225 0.86 BCL2A1 (0.66) BCL2A1MAPTALDH1A1LMNAKHK
SCHEMBL12208547 0.84 BCL2A1 (0.53) BCL2A1MAPTALDH1A1LMNAKHK
SCHEMBL20158997 0.84 KHK (0.49) BCL2A1MAPTALDH1A1LMNAKHK
SCHEMBL31084546 0.82 MAPT (0.46) BCL2A1MAPTALDH1A1LMNAKHK
SCHEMBL28283045 0.82 MAPT (0.46) BCL2A1MAPTALDH1A1LMNAKHK
SCHEMBL8108419 0.82 BCL2A1 (0.54) BCL2A1MAPTALDH1A1LMNAKHK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009001127-A1 CYANOCYCLOPROPYLCARBOXAMIDES AS CATHEPSIN INHIBITORS ASTRAZENECA AB (SE) 2008-12-31 WO disclosed